How would you treat a young premenopausal female with triple negative inflammatory breast cancer who progressed on carboplatin/paclitaxel/pembrolizumab (KEYNOTE 522), but didn't receive anthracycline portion and has a positive BRCA2 mutation?

1 Answers

Mednet Member

Medical Oncology · Mayo Clinic

I assume she had surgery already given progression. I would proceed with AC/pembro, and subsequently would continue pembro with the addition of olaparib.

Given her BRCA2 mutation, she would not be eligible for Optimice-RD.